Latest Articles

Publication Date
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - MSN

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial MSN

Published: May 23, 2026, 12:41 p.m.
Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints - Yahoo Finance

Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints Yahoo Finance

Published: May 23, 2026, 12:01 p.m.
Primary Cutaneous Endometriosis of the Umbilicus: A Diagnostic Challenge - Cureus

Primary Cutaneous Endometriosis of the Umbilicus: A Diagnostic Challenge Cureus

Published: May 21, 2026, 4:13 p.m.
ADVANTAGE: Advanced discovery of visceral analgesics by neuroimmune targets and the genetics of extreme human phenotype, a study protocol.

Chronic visceral pain affects over 20% of adults globally but remains poorly understood, significantly impacting quality of life and healthcare costs. Limited understanding and diagnostic misconceptions hinder effective management, particularly …

Published: May 21, 2026, midnight
Piezo1 mediates hypoxia-induced endometriosis fibrosis via the mtDNA -dependent cGAS-STING pathway.

Endometriosis (EMs) is a prevalent gynecological disorder characterized by the ectopic growth of functional endometrial tissue, and its fibrotic pathology represents a primary contributor to chronic pain and infertility in …

Published: May 19, 2026, midnight
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Yahoo

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Yahoo

Published: May 18, 2026, 4:44 p.m.
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Clinical Trials Arena

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Clinical Trials Arena

Published: May 18, 2026, 4:34 p.m.
Merck’s Sac-TMT met primary endpoints in endometrial cancer trial - TipRanks

Merck’s Sac-TMT met primary endpoints in endometrial cancer trial TipRanks

Published: May 18, 2026, 11:10 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!